Variety of suitable clients: CDEC reviewed the uncertainty in the volume of sufferers with moderately extreme to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical professionals consulted by CADTH indicated that some sufferers that are categorised as possessing delicate or reasonable illness could have a extreme bleeding